购物车
全部删除
您的购物车当前为空
别名 斯妥尤单抗, Ha15-10ac12.1, Ha15-10ac12, AGS15C
Sirtratumab Vedotin (ASG-15ME) 是一种抗体-药物偶联物(ADC),由靶向SLITRK6的单克隆抗体与强效细胞毒剂单甲基奥瑞他汀E(MMAE)共价连接而成。Sirtratumab Vedotin旨在将破坏微管的有效载荷MMAE选择性递送至表达SLITRK6抗原的肿瘤细胞,使其在膀胱癌和转移性尿路上皮癌研究中具有重要潜力。

为众多的药物研发团队赋能,
让新药发现更简单!
Sirtratumab Vedotin (ASG-15ME) 是一种抗体-药物偶联物(ADC),由靶向SLITRK6的单克隆抗体与强效细胞毒剂单甲基奥瑞他汀E(MMAE)共价连接而成。Sirtratumab Vedotin旨在将破坏微管的有效载荷MMAE选择性递送至表达SLITRK6抗原的肿瘤细胞,使其在膀胱癌和转移性尿路上皮癌研究中具有重要潜力。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,650 | 现货 | |
| 5 mg | ¥ 4,970 | 现货 | |
| 10 mg | ¥ 6,880 | 现货 | |
| 25 mg | ¥ 9,870 | 现货 | |
| 50 mg | ¥ 13,700 | 现货 |
| 产品描述 | Sirtratumab Vedotin (ASG-15ME) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody that targets SLITRK6 covalently linked to the potent cytotoxic agent monomethyl auristatin E (MMAE). Sirtratumab Vedotin is designed to selectively deliver the microtubule-disrupting payload MMAE to tumor cells expressing the SLITRK6 antigen, granting it significant potential for research in bladder cancer and metastatic urothelial carcinoma. |
| 别名 | 斯妥尤单抗, Ha15-10ac12.1, Ha15-10ac12, AGS15C |
| CAS No. | 1824663-82-2 |
| 存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容